Literature DB >> 16740817

Effects of breast milk on the severity and outcome of neonatal abstinence syndrome among infants of drug-dependent mothers.

Mohamed E Abdel-Latif1, Jason Pinner, Sara Clews, Fiona Cooke, Kei Lui, Julee Oei.   

Abstract

OBJECTIVE: The purpose of this research was to assess the effects of breast milk on the severity and outcome of neonatal abstinence syndrome.
METHODS: We conducted a retrospective chart review of 190 drug-dependent mother and infant pairs. Patients were categorized according to the predominant type of milk consumed by the infant on the fifth day of life (breast milk: n = 85 or formula: n = 105). The Finnegan's scoring system was used to monitor withdrawal, and medication was commenced if there were 2 scores of > or = 8.
RESULTS: Mean Finnegan scores were significantly lower in the breast milk group during the first 9 days of life even after stratifying for prematurity and exposure to polydrug and methadone. Significantly fewer infants required withdrawal treatment in the breast milk group. The median time to withdrawal occurred considerably later in breast milk group. In a multivariate analysis controlled for exposure to drugs of high risk of neonatal abstinence syndrome, polydrug, and prematurity, breast milk group was associated with lower need for neonatal abstinence syndrome treatment.
CONCLUSIONS: Breast milk intake is associated with reduced neonatal abstinence syndrome severity, delayed onset of neonatal abstinence syndrome, and decreased need for pharmacologic treatment, regardless of the gestation and the type of drug exposure.

Entities:  

Mesh:

Year:  2006        PMID: 16740817     DOI: 10.1542/peds.2005-1561

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  57 in total

1.  Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid abstinence syndrome.

Authors:  Walter K Kraft; Kevin Dysart; Jay S Greenspan; Eric Gibson; Karol Kaltenbach; Michelle E Ehrlich
Journal:  Addiction       Date:  2010-10-06       Impact factor: 6.526

Review 2.  Pharmacological Management of Opioid Use Disorder in Pregnant Women.

Authors:  Christine M Wilder; Theresa Winhusen
Journal:  CNS Drugs       Date:  2015-08       Impact factor: 5.749

Review 3.  ABM clinical protocol #21: guidelines for breastfeeding and substance use or substance use disorder, revised 2015.

Authors:  Sarah Reece-Stremtan; Kathleen A Marinelli
Journal:  Breastfeed Med       Date:  2015-04       Impact factor: 1.817

4.  Evaluating medication use in pregnancy and lactation: what every pharmacist should know.

Authors:  Betsy Walters Burkey; Amy P Holmes
Journal:  J Pediatr Pharmacol Ther       Date:  2013-07

Review 5.  Pharmacological and non-pharmacological treatments for the Neonatal Abstinence Syndrome (NAS).

Authors:  A K Mangat; G M Schmölzer; W K Kraft
Journal:  Semin Fetal Neonatal Med       Date:  2019-02-05       Impact factor: 3.926

Review 6.  Pharmacologic management of the opioid neonatal abstinence syndrome.

Authors:  Walter K Kraft; John N van den Anker
Journal:  Pediatr Clin North Am       Date:  2012-08-30       Impact factor: 3.278

Review 7.  Methadone exposure during lactation.

Authors:  Miguel Marcelo Glatstein; Facundo Garcia-Bournissen; Yaron Finkelstein; Gideon Koren
Journal:  Can Fam Physician       Date:  2008-12       Impact factor: 3.275

8.  Neonatal abstinence syndrome--postnatal ward versus neonatal unit management.

Authors:  Tolulope Saiki; Silke Lee; Simon Hannam; Anne Greenough
Journal:  Eur J Pediatr       Date:  2009-05-14       Impact factor: 3.183

9.  ABM clinical protocol #21: Guidelines for breastfeeding and the drug-dependent woman.

Authors:  Lauren M Jansson
Journal:  Breastfeed Med       Date:  2009-12       Impact factor: 1.817

10.  The effects of maternally administered methadone, buprenorphine and naltrexone on offspring: review of human and animal data.

Authors:  W O Farid; S A Dunlop; R J Tait; G K Hulse
Journal:  Curr Neuropharmacol       Date:  2008-06       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.